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Therapy 
Metformin takes a new route to clinical efficacy 
 
Marc Foretz and Benoit Viollet 
 
Refers to Duca, F. A. et al. Metformin activates a duodenal Ampk-dependent pathway to 
lower hepatic glucose production in rats. Nat. Med. http://dx.doi.org/10.1038/nm.3787 
 
Metformin is currently the first-line treatment option for patients with type 2 diabetes 
mellitus, yet its mechanism of action remains uncertain. A new study reveals the 
important role for the activation of a duodenal AMPK-dependent neuronal pathway in 
the acute antihyperglycaemic effect of metformin and the inhibition of hepatic glucose 
production.  
 
The prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic proportions 
worldwide and represents an important threat to global public health systems. On the basis of 
available clinical evidence, the American Diabetes Association (ADA) reaffirmed metformin 
as the optimal first-line therapy for patients with T2DM, unless contraindications or 
intolerance are present.1 This recommendation was made not only because metformin is 
easily accessible and affordable, but also because of the long-standing evidence base for its 
efficacy, safety (low risk of hypoglycaemic episodes) and potential benefits on multiple 
cardiovascular risk factors.1,2 However, although metformin has been prescribed for >50 years 
in Europe (it was only approved by the FDA in December 1994), its mechanism of action is 
still disputed. The action of metformin is probably dependent on a combination of distinct 
activities, as the potential mechanisms by which it has its beneficial effects include various 
organs such as the liver and the small intestine. 
 
In the past few years, much of the basic research on metformin has focused on its ability to 
suppress hepatic glucose production (HGP). Multiple underlying mechanisms with the 
mitochondria as the primary target have been described.2 For a decade, metformin-induced 
inhibition of hepatic gluconeogenesis has been ascribed to the activation of the 
serine/threonine kinase 11/ Liver kinase B1 (STK11/LKB1)–5’-AMP-activated protein kinase 
(AMPK) signalling pathway, which senses cellular energy levels and regulates the balance 
between catabolic and anabolic processes. However, this mechanism of action has been 
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seriously challenged by the use of liver-specific STK11/LKB1 and AMPK knockout mouse 
models.3,4 
 
Findings published in 2010 further established that metformin acts through AMPK-
independent mechanisms to lower HGP.3 Indeed, metformin-dependent inhibition of complex 
I of the mitochondrial electron transport triggers a decrease in the cellular ATP:AMP ratio, 
which results in low levels of ATP that are insufficient to drive energy-consuming hepatic 
gluconeogenesis. In addition, a metformin-induced increase in AMP levels leads to the 
inhibition of adenylate cyclase and of the induction of gluconeogenesis by glucagon.4 AMP is 
also a potent allosteric inhibitor of fructose 1,6-bisphosphatase, a key enzyme in 
gluconeogenesis. Furthermore, inhibition of glycerol-3-phosphate dehydrogenase in the 
mitochondria results in an altered cellular redox state and limits the contribution of lactate and 
glycerol to hepatic gluconeogenesis.5 The intestine also contributes to the overall glucose-
lowering effect of metformin and might be an important site of action of this drug.6 Increased 
intestinal use of glucose, which enhances anaerobic metabolism of glucose to lactate, 
increases glucose turnover and supports the antihyperglycaemic action of the drug. In 
addition, it should be noted that oral dosing produces a stronger and longer glucose-lowering 
response than metformin administered intravenously and metformin accumulates in the 
intestinal mucosa to a greater extent than it does in the liver, which supports the notion that 
the gastrointestinal tract is an important target organ for metformin.6 
 
The recent study reported by Duca et al.7 proposes a new paradigm for the diverse modes of 
action of metformin. Previous findings had highlighted the importance of nutrient sensing in 
the gut for triggering a neuronal negative-feedback system for glucose homeostasis. Duca and 
co-workers went on to show that preabsorptive metformin lowers HGP through a gut–brain–
liver neuronal network.7 This effect was observed when metformin (50 mg kg-1 or 200 mg kg-
1) was infused directly into the duodenal lumen of insulin-resistant rats, but not when it was 
delivered via the portal vein. By using a combination of pharmacological approaches, Duca 
and colleagues uncover the cellular mechanisms underlying the action of metformin on 
intestinal mucosa and subsequent inhibition of HGP. 
 
Duca and colleagues attribute the effect of duodenal infusion of metformin to the release of 
glucagon-like peptide 1 (GLP-1), probably from the enteroendocrine L cells, and activation of 
the GLP-1 receptor (GLP1R) on the afferent vagus nerve innervating the small intestine to 
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trigger a gut–brain–liver axis that regulates HGP (Figure 1). They hypothesize that 
metformin-induced activation of AMPK in the intestinal mucosa could stimulate the release 
of GLP-1. This theory is consistent with other findings that metformin and the AMPK agonist 
5-aminoimidazole-4-carboxamide 1‐‐D‐ribofuranoside (AICAR) are GLP-1 
secretagogues.8 Duca et al. infected the duodenum of insulin-resistant rats with an adenovirus 
encoding a dominant-negative mutated form of AMPK, which showed that duodenal AMPK 
is required for the preabsorptive action of metformin. However, it was not possible to 
determine the specific contribution of cells that produce GLP-1 and/or other cell types in the 
therapeutic benefit of metformin-induced activation of AMPK. In addition, it remains unclear 
whether locally produced GLP-1 (acting directly on close afferent neurons) and/or enhanced 
circulating levels of GLP-1 (for distant hormonal actions) are a prerequisite for the acute 
therapeutic effect of metformin. Unfortunately, the study lacks information on plasma levels 
of GLP-1 during and after intraduodenal treatment. 
 
The authors showed that the signal to release GLP-1 that is induced by metformin is relayed 
by the activation of GLP1R on vagal afferent neurons through effects on a neuronal network. 
This action was demonstrated by co-infusion with the GLP1R antagonist exendin-9, chemical 
denervation and vagotomy that completely eliminated the effects of metformin in the 
duodenum on HGP. Curiously, this result contrasts with a previous report demonstrating that 
the acute glucoregulatory actions of metformin are independent of GLP1R.8 Further 
elucidation of the mechanisms underlying the action of metformin in the duodenum will 
benefit from animal models that target AMPK and intestinal signalling molecules. 
 
One intriguing question raised by this work is the contribution of the acute action of 
metformin in the duodenum in clinical settings, in which patients are usually exposed to 
metformin for long periods of time. Interestingly, an increasing amount of evidence suggests 
that metformin ‘shapes’ the metabolic plasticity of the gastrointestinal tract by inducing 
alteration in the recirculation of bile acids and the composition of the gut microbiota, which 
results in enhanced GLP-1 secretion in patients with T2DM.9 Thus, acute and chronic 
glucose-lowering effects of metformin might be largely mediated by a combination of 
intestinal and direct hepatic mechanisms. 
 
Collectively, these results provide compelling evidence that metformin targets a duodenal 
AMPK-dependent neuronal network to regulate HGP. A major implication of these findings 
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is that AMPK could be a primary therapeutic target within the intestine to restore impaired 
glucose homeostasis in T2DM. Interestingly, Duca and co-workers showed that intraduodenal 
infusion of the small molecule AMPK activator A-769662 mimicked the effect of 
intraduodenal metformin infusion.7 Of note, activation of duodenal AMPK with the 
polyphenol resveratrol also initiates a gut–brain–liver axis to lower HGP.10 Whether these 
new insights could lead to therapeutic strategies in humans remains to be determined. 
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Figure legend 
 
Figure 1: Metformin lowers hepatic glucose production through a gut–brain–liver axis. 
Metformin activates duodenal AMPK, induces the enteroendocrine L cells to release GLP-1 
and triggers a gut–brain–liver neuronal network to regulate hepatic glucose production. 
Abbreviations: AMPK, AMP-activated protein kinase; GLP-1, glucagon-like peptide 1; 
GLP1R, GLP-1 receptor; NTS, nucleus tractus solitarius. 
 
Pullquotes 
...metformin-induced activation of AMPK in the intestinal mucosa could stimulate the release 
of GLP-1 
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